Better Health for All

Keen Vision Acquisition Corporation (KVAC) is merging with Medera Inc., a clinical-stage biotechnology company.

Medera's core business is entirely focused on developing gene and cell-based therapies and bioengineered human mini-heart technology for difficult-to-treat cardiovascular diseases (HFrEF, HFpEF, DMD-CM), indicating a substantial positive health impact. As a clinical-stage company, Medera is not currently generating revenue from commercial products, thus it has no revenue from products with negative health outcomes. The company's entire operational focus is on research and development for health improvement, which means 100% of its R&D is allocated to improving health outcomes. Medera has received FDA IND clearances for three ongoing clinical trials, and Fast Track and Orphan Drug Designations for specific therapies. However, the articles do not provide specific data on the ethical conduct of clinical trials beyond regulatory clearances, nor do they detail any preventative health measures.

Fair Money & Economic Opportunity

No relevant data was found in the provided article to assess KVAC.US against the 'Fair Money & Economic Opportunity' ethical value.

The article explicitly states, "No relevant articles found. No data was extracted for the requested metrics."

Kind to Animals

Medera, which is merging with KVAC, extensively uses bioengineered human-based mini-Heart technology and human stem cell tissue models for drug discovery and screening.

These alternative methods are standard in product development and safety dossiers, having supported FDA Investigational New Drug (IND) and Fast Track Designation (FTD) applications. The company's policy aligns with the FDA Modernization Act 2.0, actively leading the charge toward human-based preclinical models as ethical and superior alternatives to animal testing. Medera has collaboration and licensing arrangements with global pharmaceutical leaders, co-developing human-based mini-Heart models with Pfizer and AstraZeneca. The partnership between Novoheart (Medera's subsidiary) and Curi Bio is a collaboration focused on animal-free research and development, with the integrated platform estimated to improve efficiency by as much as 100-fold. The company is aligned with the FDA Modernization Act 2.0, which calls for the development of superior human-based alternatives to traditional animal testing.

No War, No Weapons

Keen Vision Acquisition Corporation (KVAC.US) is a blank check company that intends to focus on businesses in the healthcare industry.

It is merging with Medera Inc., a clinical-stage biotechnology company focused on gene therapies for cardiovascular diseases. The company's investment strategy targets agriculture, biotechnology, and consumer products. There is no evidence in the provided articles to suggest that KVAC.US or Medera Inc. has any involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding initiatives, or any other defense or conflict-related activities. The company's core business and its merger target are entirely outside the scope of the 'No War, No Weapons' value.

Planet-Friendly Business

No specific quantitative data or concrete actions related to planet-friendly business practices are available for KVAC.US.

The company is a blank check company (SPAC), and the provided articles focus on its IPO, investment strategy, and team experience. One article explicitly states that sustainability data is currently not available for KVAC.US. While the company is described as an "ESG-focused SPAC," this is a general descriptor of its investment intent and not evidence of specific environmental performance or initiatives by KVAC.US itself.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles to assess KVAC.US against any of the KPIs for 'Respect for Cultures & Communities'.

All articles were placeholders and explicitly stated a lack of relevant information regarding the company's practices, partnerships, investments, or incidents related to cultural and community respect.